Core Viewpoint - The chemical pharmaceutical sector experienced a significant increase of 2.47% on July 29, with Nanjing Pharmaceutical leading the gains [1] Group 1: Market Performance - The Shanghai Composite Index closed at 3609.71, up 0.33% [1] - The Shenzhen Component Index closed at 11289.41, up 0.64% [1] Group 2: Individual Stock Performance - Nanjing Pharmaceutical (681899) closed at 11.90, with a rise of 17.01% and a trading volume of 388,700 shares, totaling a transaction value of 417 million yuan [1] - Yuandong Biological (688513) closed at 65.92, up 15.45%, with a trading volume of 74,200 shares and a transaction value of 466 million yuan [1] - Microchip Biotech (688321) closed at 38.37, increasing by 12.85%, with a trading volume of 401,800 shares and a transaction value of 1.49 billion yuan [1] - Aoxiang Pharmaceutical (603229) closed at 10.54, up 10.02%, with a trading volume of 480,600 shares and a transaction value of 493 million yuan [1] - Asia-Pacific Pharmaceutical (002370) closed at 6.81, also up 10.02%, with a trading volume of 1,937,200 shares and a transaction value of 1.285 billion yuan [1] - Chenxin Pharmaceutical (603367) closed at 25.93, up 10.01%, with a trading volume of 160,000 shares and a transaction value of 413 million yuan [1] - Fuyuan Pharmaceutical (6801089) closed at 22.90, increasing by 9.99%, with a trading volume of 176,900 shares and a transaction value of 389 million yuan [1] - Nikan Pharmaceutical (688658) closed at 33.02, up 9.96%, with a trading volume of 118,700 shares and a transaction value of 376 million yuan [1] - Luoxin Pharmaceutical (002793) closed at 5.97, increasing by 9.94%, with a trading volume of 421,300 shares and a transaction value of 240 million yuan [1] - Frontier Biotech (688221) closed at 22.42, up 9.74%, with a trading volume of 471,400 shares and a transaction value of 1.023 billion yuan [1] Group 3: Capital Flow - The chemical pharmaceutical sector saw a net inflow of 1.295 billion yuan from main funds, while retail funds experienced a net outflow of 1.198 billion yuan [1] - Speculative funds recorded a net outflow of 97.108 million yuan [1]

Group 1 - The core viewpoint highlights the strong performance and liquidity of the Science and Technology Innovation Pharmaceutical ETF managed by Harvest, which has seen significant trading activity and growth in both scale and shares [2] - As of July 28, the ETF recorded a turnover rate of 22.91% and a transaction volume of 48.1073 million yuan, indicating active market participation [2] - The ETF's net asset value increased by 54.52% over the past year, ranking it in the top 12.25% among comparable index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - Recent collaboration between Hengrui Medicine and GlaxoSmithKline (GSK) involves the joint development of up to 12 innovative drugs, with GSK making an initial payment of 500 million USD and potential milestone payments totaling around 12 billion USD [4] - The pharmaceutical industry is experiencing high growth, with recommendations for companies in Pharma and Biopharma/Biotech sectors as they enter a phase of performance expansion [5]

Group 1: Company Performance - WuXi AppTec reported a net profit of 8.561 billion yuan for the first half of the year, a year-on-year increase of 101.92% [1] - The company's revenue for the first half reached 20.799 billion yuan, reflecting a growth of 20.64% year-on-year [1] - WuXi AppTec plans to distribute a cash dividend of 3.5 yuan per share to all shareholders [1] - The company has revised its revenue forecast for the full year to between 42.5 billion and 43.5 billion yuan [1] - SANY Heavy Industry plans to issue non-financial corporate debt financing tools not exceeding 20 billion yuan to optimize its financing structure [1] Group 2: Film Industry Impact - Happiness Blue Sea announced that the film "Nanjing Photo Studio" has surpassed 412 million yuan in cumulative box office, exceeding 50% of the company's audited revenue for the most recent fiscal year [2] - The film's impact on the company's revenue is currently negligible as it is still in theaters [2] Group 3: Corporate Actions - Zhonghua Equipment plans to issue shares to acquire 100% equity of two companies, marking a significant asset restructuring [2] - Dahua Intelligent is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure [3] - Shiming Technology's actual controller and chairman has been placed under detention due to personal matters unrelated to the company [4] Group 4: Financial Performance - Ju Chen Co. reported a net profit growth of 43.5% for the first half of the year [6] - Qizheng Tibetan Medicine's net profit increased by 9.94% year-on-year [6] - China Minmetals' new contract value decreased by 19.1% year-on-year [6] - Huicheng Environmental's net profit declined by 85.63% year-on-year [6] Group 5: Mergers and Acquisitions - Kaishan Holdings plans to acquire a minority stake in SMGP for 3 million USD [6] - Zhonghua International intends to purchase 100% equity of Nantong Xingchen Composite Materials Co., Ltd. [6] - Xiangdian Co. plans to acquire a 12.5% stake in Tongda Electromagnetic Energy for 208 million yuan [6]

证券代码：688513 证券简称：苑东生物 公告编号：2025-053 成都苑东生物制药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%整数倍的提示性公告 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、成 都菊苑投资合伙企业（有限合伙）（以下合称"转让方"）保证向成都苑东生物制药 股份有限公司（以下简称"苑东生物"或"公司"）提供的信息内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的出让方为苑东生物员工持股平台，为苑东生物控股股东、实 际控制人、董事长王颖控制的企业，非苑东生物的控股股东、实际控制人、董事、 高级管理人员及核心技术人员。出让方与王颖互为一致行动人，合计持股比例超过 总股本的 5%。公司控股股东、实际控制人、董事长王颖直接或间接持有的股份不 参与本次询价转让。 （二）转让方一致行动关系及具体情况说明 本次询价转让的转让方成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合 伙企业（有限合伙）、成都菊苑投资 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-052 成都苑东生物制药股份有限公司 关于自愿披露培哚普利氨氯地平片（Ⅲ）获得 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）全资子公司成都硕德药 业有限公司（以下简称"硕德药业"）于近日收到国家药品监督管理局（以下简 称"国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 剂型：片剂 规 格 ： 每 片 含 精 氨 酸 培 哚 普 利 10mg 、 苯 磺 酸 氨 氯 地 平 5mg （ 按 C₂₀H₂₅N₂O₅Cl 计） 注册分类：化学药品 4 类 药品有效期：24 个月 上市许可持有人：成都硕德药业有限公司 生产企业：成都硕德药业有限公司 药品注册标准编号：YBH17072025 受理号：CYHS2401223 证书编号 2025S02256 药品批准文号：国药准字 H20254925 药品名称：培哚普利氨氯地平片（Ⅲ） 根据《中华人民共和国药品管理法》 ...

中信证券股份有限公司 关于成都苑东生物制药股份有限公司 股东向特定机构投资者询价转让股份的核查报告 上海证券交易所： 中信证券股份有限公司（以下简称"中信证券"或"组织券商"）受委托担任成都 楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、成都菊苑投资 合伙企业（有限合伙）（以下合称"转让方"）以向特定机构投资者询价转让（以下简 称"询价转让"）方式减持所持有的成都苑东生物制药股份有限公司（以下简称"公司" 或"苑东生物"）首次公开发行前已发行股份的组织券商。 经核查，中信证券就本次询价转让的股东、受让方是否符合《上海证券交易所科创 板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修订）》（以下简 称"《询价转让和配售指引》"）要求，本次询价转让的询价、转让过程与结果是否公 平、公正，是否符合《询价转让和配售指引》的规定作出如下报告说明。 一、本次询价转让概况 （一）本次询价转让转让方 截至 2025 年 7 月 22 日，转让方所持公司首发前股份的数量及占公司总股本比例情 况如下： | 序号 | 股东名称 | 持股数量（股） | 持股比例 | | --- | --- ...

苑东生物(688513.SH)公告称，全资子公司硕德药业于近日收到国家药监局核准签发的《药品注册证 书》，药品名称为培哚普利氨氯地平片（Ⅲ）。该药品为复方制剂，主要用于治疗 高血压。培哚普利 氨氯地平片（Ⅲ）由法国施维雅开发，最早于2008年3月在欧盟获批上市。硕德药业该药品获批后视同 通过一致性评价。根据米内网数据，2024年该药品销售金额约4.36亿元。 ...

Core Viewpoint - Yuan Dong Bio is accelerating its transformation from generic to innovative drugs, with a strong commitment to innovation as the core driver of high-quality development [2][4]. Company Overview - Chengdu Yuan Dong Bio-Pharmaceutical Co., Ltd. was established in 2009 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 2, 2020, with stock code 688513 [4]. - The company focuses on research and development driven by innovation, integrating the entire industry chain of chemical raw materials, high-end chemical drugs, and biological drugs [4]. - Yuan Dong Bio aims to become a leading enterprise in the global anesthesia and analgesia field, with a mission centered on patient care and human health [4]. New Quality Productivity - The core of "new quality productivity" in the biopharmaceutical industry lies in technological innovation and the transformation of results [5]. - A multi-dimensional collaborative breakthrough is essential for cultivating new quality productivity, requiring technological innovation, policy support, and a complete industrial development ecosystem [5]. Business Strategy - The company’s development strategy is based on high-end generic drugs, internationalization for growth, and innovation for the future [6]. - High-end generic drugs currently serve as the main source of revenue and profit, with a steady increase in the number of approvals over the past three years [6]. - As of the end of 2024, the company has successfully industrialized 60 high-end chemical drugs, including several first generics and special narcotic drugs [6]. International Expansion - Yuan Dong Bio is actively developing international markets while deepening its domestic market presence [6]. - By the end of 2024, the company has exported 12 raw materials to major international markets and received FDA approval for 2 high-end formulation products [6]. Innovation and R&D - The company maintains a high level of R&D investment, with over 20% of revenue allocated to R&D in recent years, exceeding the industry average [8]. - There are currently over 10 first-class new drugs in the R&D pipeline, ensuring a structured layout for industrial upgrades [7][8]. - The efficiency of R&D results transformation is continuously improving, with an increasing number of product approvals in high-end generics and several new drug pipelines at different stages of development [8]. Future Outlook - Yuan Dong Bio is committed to developing differentiated clinical advantages in innovative products and high-end formulations to enhance market competitiveness [9].

Group 1 - The preliminary transfer price for the shares is set at 42.06 yuan per share based on the inquiry conducted on July 23, 2025 [1] - A total of 12 institutional investors participated in the inquiry, including fund management companies, insurance companies, securities companies, and private equity fund managers, with a total effective subscription of 5,400,000 shares, resulting in a subscription multiple of 1.60 times the transfer base price [1] - The total number of shares to be transferred has been fully subscribed, with the preliminary number of institutional investors set to acquire the shares being 10, totaling 3,369,550 shares [2]

Group 1 - Rongzhi Rixin expects a net profit increase of 2,027.62% to 2,179.59% for the first half of 2025, with projected profits between 14 million to 15 million yuan [1] - The significant profit growth is attributed to the acceleration of digital and intelligent transformation across industries, leading to increased revenue from sectors like wind power and petrochemicals [1] - The company has improved operational management efficiency, resulting in enhanced gross margins and overall profitability [1] Group 2 - Jinzhai Food plans to repurchase shares worth between 50 million to 100 million yuan, with a maximum repurchase price of 16 yuan per share [2] - The repurchase will be funded through self-owned funds and a special loan from China Merchants Bank, with a loan commitment of up to 90 million yuan [2] Group 3 - Zhongfu Information's chairman and general manager, Wei Dongxiao, has been detained, and the board has arranged for the deputy general manager to assume his responsibilities during this period [3][4] - The company states that this situation will not significantly impact its daily operations [4] Group 4 - Shenzhen Energy plans to invest approximately 789.703 million yuan in the construction of the Honghaiwan offshore wind power project, with a portion funded through financing [6] - The company will increase its capital in its subsidiary by 153.108 million yuan to support this project [6] Group 5 - *ST Zitian faces potential delisting due to failure to rectify false financial reporting as mandated by the China Securities Regulatory Commission [8] - The company has not disclosed corrected financial reports within the required timeframe, leading to a warning of delisting risk [8] Group 6 - Watson Bio has signed a strategic cooperation framework agreement with Yuxi State-owned Capital Operation Co., aiming to establish a long-term partnership in the vaccine and bioproducts industry [10] - The collaboration is expected to enhance innovation and business expansion in the vaccine sector [10] Group 7 - Weiming Environmental reported a total power generation of 226,162.29 million kWh in the first half of 2025, representing a year-on-year increase of 7.54% [12] - The company also recorded a total waste input of 689.32 million tons, with a growth of 8.71% compared to the previous year [12]